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Stroke patients who lose the ability to produce language (aphasia) often remain able to 
sing. This observation has stimulated interest in a structured music therapy, Melodic 
Intonation Therapy, for post-stroke aphasia. While existing studies find positive 
outcomes with Melodic Intonation Therapy, its efficacy has yet to be substantiated by 
adequately powered, randomized, controlled trials. Focusing on acute stroke patients, we 
aim to determine the impact of melodic intonation therapy versus usual care on aphasia 
recovery. The study will be a single blind, randomized controlled trial with modified 
melodic intonation therapy and usual care groups. Aphasia severity will be scored at 
baseline and 3 weeks, and the mean difference from baseline will be compared across 
groups. Post-stroke aphasia has high morbidity and mortality and profoundly impedes 
daily living. Its rehabilitation is imperative. In the absence of standard of care, my results 




CHAPTER 1: INTRODUCTION 
 
1.1 Background 
A. Epidemiology of Stroke and Aphasia 
Each year, approximately 795,000 Americans experience stroke, with an overall 
adult stroke prevalence of 2.7%, projected to increase by 20.5% to 2030.1-3 Stroke is now 
the 5th leading cause of death in the U.S., however, stroke mortality has been declining, 
with a 33.7% decline in the age-adjusted stroke death rate over 2003 – 2013.1-3 While the 
decline in stroke mortality is good news, morbidity remains high; an increasing number 
of stroke patients survive, with but with moderate to severe disability (15-30%) or 
moderate functional impairment (40%).4  
A common and particularly devastating impairment that results from stroke is 
aphasia. Estimates of post-stroke aphasia vary with selection of the study population and 
assessment timing and instrument. Most incidence evidence comes from Europe. In a 
prospective community based study of consecutive acute-stroke patients (N = 881) in a 
pre-specified catchment area, incidence of aphasia on admission was found to be 38%.5  
A large series (N = 11,572) of unselected randomly sampled hospitalized acute-stroke 
patients found aphasia incidence of 28%.6 In a 1-year, prospective, population based 
study of a pre-specified catchment area with 188,015 inhabitants, 30% of first ever stroke 
patients had aphasia.7 In a prospective sample (N = 106) of every 4th acute stroke patient 
admitted to a Swedish hospital, 33% were found to be aphasic.8 Finally, 34.8% of 
consecutive patients (N = 2,389) from a dedicated cognitive stroke registry of an 
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American tertiary care facility were found to have aphasia when assessed within 1 month 
of stroke onset.9  
The natural history of aphasia is variable and poorly understood. Study of 
spontaneous recovery is complicated because baseline assessment should be conducted 
early to precede early cortical re-organization10 but may be difficult to accomplish in 
unstable patients.8 Additionally, transient perfusion-related defects may resolve without 
developing into full aphasia syndromes.11 Inter- and intra-study variability in assessment 
timing introduces spurious variation in aphasia scores, and the different aphasia 
assessment instruments have varied and imperfect ability to classify aphasia syndromes.12 
 Studies of spontaneous aphasia recovery find that most improvement occurs 
within the first 3 months after stroke onset, with improvement attenuating subsequently 
until it plateaus, typically within 1 year.5,11,13-17 In a longitudinal study of 24 patients from 
a Veterans Administration Medical Center (VAMC) followed for 2-years with language 
assessment at 1, 2, 6, 12, 18, and 24 months, paired t-tests revealed significant aphasia 
reduction (p < .01) in all but the final 6 months, with greatest recovery in the first 
followed by the next 6 months, although 22 of these patients underwent unquantified 
treatment that may confound results.15 In a 1-year prospective study of 106 consecutive 
first time ischemic stroke patients presenting to a single center, 2/3 of patients diagnosed 
with aphasia remained aphasic at 12 months.17 In an unselected sample of N = 119 post-
stroke aphasic patients who underwent serial language assessment, at 18 months, 24% 
had recovered completely, 21% had died, and 43% still had significant aphasia.8  
 3 
B. Consequences of Post-Stroke Aphasia 
Post-stroke aphasia is costly, disabling, and deadly, in both the short and the 
longer term. In a cohort (N = 3200) of Medicare patients from North Carolina with 
ischemic stroke, at one year, attributable costs (Medicare payments) of aphasia were 
estimated to be $1703 using multi-variate analysis, 8.5% higher than general stroke care 
attributable costs in the absence of aphasia.18  During the acute period after stroke, 
persons with aphasia (PWA) have longer hospital stays,18-20 more inpatient 
complications,21 and higher inpatient mortality rates8,19,20 than persons without aphasia. 
In the longer term, among survivors of stroke, PWA have greater rates of 
depression (33% compared with 11% at 12 months, p=.033)17 and other morbidity.6,8,22,23 
In 11,572 unselected hospitalized acute stroke patients, at 2 years, PWA had greater 
disability (odds ratio [OR] 1.74, 95% confidence interval [CI]: 1.55–1.96) and less 
frequently lived at home (OR 1.39, 95% CI: 1.17–1.65) than those without aphasia,6 and 
in a 10 year prospective cohort study of 2,297 hospitalized stroke patients, 
moderate/severe aphasia independently predicted dependence after controlling for initial 
stroke severity and medical complications.  
Finally, PWA have significantly higher rates of mortality than stroke survivors 
without aphasia at 2 years (OR 2.09, 95% CI 1.89–2.32),6 and at 10 years (hazard ratio 
1.50, 95% CI 1.24–1.84).23  
C. Neural Basis of Speaking, Aphasia, and Recovery 
 
Language maps to regions in the perisylvian cortex and the tracts that connect 
them. Wernicke’s territory, located in the posterior superior temporal gyrus, receives 
input from the auditory cortex and assigns word meanings. The arcuate fasciculus 
 4 
connects Wernicke’s territory to Broca’s territory in the posterior inferior frontal gyrus, 
which in turn innervates motor neurons that control facial muscles to produce speech.24  
Additionally, recent imaging has shown that Geschwind’s territory (the angular and 
supramarginal gyri) connect to both Broca’s and Wernicke’s territories by large tracts 
providing a second, parallel pathway for language.25 Productive language is typically left-
oriented, while receptive language is often bilateral.26 However, functional imaging has 
revealed a spectrum of left-right lateralization in the general population, and using 
transient focal virtual lesions in healthy subjects, individual heterogeneity in degree and 
side of lateralization as well as degree of bi-laterality has been shown to affect language 
disruption.27         
Stroke disrupts blood supply, resulting in infarction with ultimate necrosis of 
tissue, hypo-perfusion of the surrounding ischemic penumbra, and diaschisis, disruption 
of distant and structurally normal structures due to disruption of the axonal pathway to 
those structures.28  If the infarction occurs in the left perisylvian regions discussed above, 
aphasia results. 
From clinical observation and neural imaging studies, it is known that the brain 
undergoes profound reorganization of structure and function after stroke. The neurologic 
mechanism underlying spontaneous post-stroke aphasia recovery has been attributed to 
activation of preserved left peri-lesional regions,29 activation of right homotopic 
regions,30 or both.31,32 These disparate patterns in lateralization of recovery can now been 
understood as different cortical activation patterns over time post-stroke, identified in a 
landmark study with serial functional magnetic resonance imaging (fMRI) for one year 
after stroke.10 Right hemispheric activation increases, with acutely decreased left 
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hemispheric activity, in the initial 2 days to 2 weeks post stroke, and correlates (r = .92) 
better than any other dynamic activation pattern with improving language function. 
However, in the chronic phase (mean 321 days post-stroke), there is re-normalization 
with a return of activation to the left hemisphere.10 This has important implications for 
post-stroke aphasia care: there is scope for therapy at all stages of recovery, but ideally, it 
would be specifically tailored to harness activation of cortical structure most implicated 
at each stage of recovery. 
D. Treatment for Post-Stroke Aphasia 
Aphasia is not a single uniform disorder: fluency, comprehension, repetition, 
naming, and/or information content may be impaired. Different patterns of impairment 
(typically reflecting lesion location and size) have been used to classify aphasia 
taxonomically (e.g. global, Broca’s, Wernicke’s), beyond the gross distinction between 
non-fluent (expressive) and fluent (receptive) aphasia.33 Different aphasia types have 
been observed to have heterogenous susceptibility to spontaneous and thus presumably 
therapy mediated recovery.8,34-36 
Historically, aphasia was thought to be irreparable, with any functional 
improvement over time resulting from spontaneous recovery, leaving no role for 
therapeutic intervention.37,38  However, in the last few decades, neuroplasticity, is widely 
accepted to occur on the basis of animal models and imaging studies.39,40 It is now 
believed that rehabilitative therapy can augment spontaneous recovery, especially if well-
timed and well-aligned with a hypothesized “critical period” of neural plasticity.39  
Additionally, while adequately powered randomized controlled trials (RCTs) have been 
scarce, a large body of experimental research, program evaluation data, and case studies 
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have found positive effects of therapeutic intervention delivered by speech language 
pathologists (SLPs), such that it is now considered to be unethical to withhold therapy 
from PWA, and this is reflected in current clinical guidelines.4,37,41  
The most common practice is for an SLP to formally assess the PWA to then 
design and manage individualized therapy, specific to the patient’s particular deficits, 
comorbidities, and psychosocial situation, drawing on a large and diverse set of 
established therapeutic approaches to optimize functional improvement42,43   
In this paper, we focus on one of the oldest and most formalized therapeutic 
approaches: Melodic Intonation Therapy (MIT).44,45 MIT was developed in response to 
the longstanding clinical observation that patients with severe expressive aphasia who are 
unable to speak, are often able to sing familiar songs.46 It was thought that through 
structured use of melody and rhythm, which are processed in the right hemisphere, 
patients could overcome left hemispheric infarcts and learn a new and permanent way to 
speak.47   
1.2 Statement of the Problem 
Aphasia is a common and devastating impairment resulting from stroke and from 
a pathophysiologic perspective, rehabilitative therapy has the potential to interact with 
neuroplasticity to augment spontaneous recovery, however, there are no clear guidelines 
on when to initiate what type of therapy. The American Heart Association/American 
Stroke Association (AHA/ASA) states that “For individuals with stroke-induced aphasia, 
speech and language therapy is recommended (Level A Recommendation, Class I 
Evidence).” However, they do not specify timing, format, intensity, frequency, or 
duration of treatment: “A variety of different treatment approaches for aphasia may be 
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useful, but their relative effectiveness is not known. (Level B recommendation, Class IIb 
Evidence).”41 Synthesis of the evidence from randomized controlled trials (RCTs) 
provides no additional guidance: a Cochrane review of 38 trials with pooled N = 1242 
found insufficient evidence to establish the effectiveness of one therapeutic approach 
over another.43 When to initiate what kind of therapy remains an open question. 
As one of the first structured aphasia programs with enduring use worldwide 
today,48 MIT is therapeutic approach that has accumulated positive case series 
evidence,44,45,49-56 however, such study designs are inherently limited by their inability to 
control for patient selection, confounding individual heterogeneity, spontaneous 
recovery, and Hawthorne effects, and cannot link MIT with aphasia recovery causally. 
Moreover, the MIT case literature has studied predominantly chronic patients, whereas 
the neural mechanisms underlying recovery are dynamic and likely to favor earlier 
treatment,57 and practically, chronic patients are unlikely to receive treatment, at least in 
the United States, where insurance reimbursement poses a binding constraint.58 MIT has 
not been studied where it might have the greatest clinical impact. 
Evidence from 3 small, recent RCTs57,59,60 is encouraging, but incomplete. In a 
waiting-list controlled crossover trial with a sub-acute study population, communication 
improved more in the group treated with MIT than in the group receiving alternative 
speech language therapy (SLT) (p < .05), and after cross-over, and communication 
improvement was greater when MIT was delivered earlier than when it was deferred (p 
=.001).60 Using the same study design with a chronic study population, the same authors 
found no difference between groups.59 Taken together, these results suggest relative 
efficacy of MIT (compared with SLT) if initiated sooner rather than later in sub-acute 
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patients, however they must be interpreted with caution. In both studies, subject 
withdrawal resulted in inadequate power, with visibly large standard errors that may have 
led to an inflated estimate of effect size61 in the sub-acute population where findings were 
significant, and/or may have led to an undetectable effect in the chronic population. 
Nonetheless, these studies underscore a need for an adequately powered RCT with earlier 
initiation of MIT to establish its efficacy. An RCT protocol undertook precisely this task 
in another underpowered, study and found greater reduction (p=.02) in aphasia severity in 
the Modified MIT (MMIT) group than the no therapy control group after just one 15-
minute session.57 While it is difficult to infer a treatment effect from a single successful 
session and the persistence of benefit was unstudied, the finding of an effect of early MIT 
even at such a low therapeutic dose, demonstrates the feasibility of early MIT stroke and 
further impels its study in an adequately powered RCT with an acute study population.  
There is no standard of care regarding what type of aphasia treatment to begin at 
what time, yet neuroimaging studies suggest that the “critical period”39 of enhanced 
neuroplasticity occurs early, at a time when PWA typically receive no formal therapy. In 
light of promising evidence of positive outcomes from early MIT, a well-designed RCT 
comparing MIT with usual care in the first days to weeks after stroke, would establish 
whether this long-standing and widely used therapy is efficacious and might serve as a 
cornerstone of early post-stroke aphasia treatment. 
1.3 Study Goals and Objectives 
 This study aims to determine if a short course of MMIT enhances aphasia 
recovery (reduces aphasia severity) more than usual care, when initiated in patients with 
non-fluent aphasia 3 days post-stroke. Because on this timeline, usual care consists of 
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assessment but no formal therapy, treatment effect estimates from this comparison 
correspond to efficacy of MMIT for this population. If MMIT is associated with a 
clinically significant reduction in aphasia severity, it could be incorporated into early 
post-stroke care. 
 The objectives of the study are to: 1) enroll a sufficient number of patients who 
meet inclusion criteria and do not meet exclusion criteria and randomize them into two 
comparable groups: Modified MIT or usual care; 2)  test whether MMIT is associated 
with a greater decrease from baseline aphasia severity (as measured by the Western 
Aphasia battery Aphasia Quotient) than usual care after the 3 week experimental period, 
and; 3) determine whether at 6 month follow-up following the 3 week experimental 
period and an additional 5 months of usual sub-acute care offered to both groups and 
delivered outside of experimental conditions, difference in aphasia from baseline differs 
across the 2 groups. 
1.4 Hypothesis 
 We hypothesize that in non-fluent aphasia patients in the acute period following 
stroke, the mean difference from baseline aphasia severity will be at least 15.10 (standard 
error [SE] 17.71) points at 3 weeks in patients randomized to receive MMIT compared 
with those who receive usual care. 
1.5 Definitions 
Acute period: Treatment with MMIT or usual care will begin 3 days post-stroke. 
Aphasia severity: Aphasia severity will be measured by the Western Aphasia Battery 
Aphasia Quotient (WAB-AQ), scale of 0 – 100, from most to least severe. 
MMIT: Modified Melodic Intonation Therapy (MMIT) delivered by an SLP. 
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CHAPTER 2: REVIEW OF THE LITERATURE 
2.1 Literature Search Criteria 
 A thorough literature search was conducted between July 2017 and July 2018 
using Pubmed and Ovid MEDLINE. Keywords used initially to identify relevant (English 
language) articles included combinations of aphasia, stroke, music, therapy, 
rehabilitation, melodic, singing. All RCTs, controlled studies, and systematic reviews 
were retained for thorough review. High quality case series, and prospective and 
retrospective cohort studies were also included when topical. Full text was acquired for 
articles deemed to be relevant on abstract screening. This process culminated in close, 
annotated reading of 211 peer-reviewed articles. 
2.2 Clinical Impact of Therapy for Persons with Aphasia: Review of Relevant Trials 
A. Efficacy of Therapy 
 To evaluate efficacy of speech language therapy (SLT) with an RCT, the control 
group must receive no formal therapy; a comparison between 2 therapeutic approaches 
can only demonstrate that one is more efficacious than the other. Few RCTs have done 
this because regardless of efficacy, it has been common practice to offer SLT in the sub-
acute phase following stroke and withholding it has been considered to be unethical in 
recent times. Although AHA/ASA guidelines recommend SLT, evidence of its efficacy is 
equivocal, with RCTs that find SLT versus no SLT to be effective,1-5 and others that find 
no difference in outcomes comparing SLT with no SLT.6-10 The major difficulty in 
inferring efficacy of SLT from studies with positive findings is that results do not 
generalize beyond the particular therapeutic approach, timing, and intensity under study. 
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 In the largest positive, a crossover designed allowed comparison of SLT with no 
SLT in the first period. 121 sub-acute subjects (2-24 weeks post stroke) were randomized 
to therapist administered SLT, volunteer administered SLT, or deferred (i.e. no initial) 
SLT. With repeated measures ANOVA, aphasia improved significantly (p<.05) in the 
two arms receiving SLT relative to the no SLT arm at the first endpoint of 12 weeks, and 
the magnitude of the treatment effect was clinically significant with a 40% increase in the 
Porch Index of Communicative Ability (PICA).11 However, 23 % of subjects did not 
complete the study (although reassuringly completion rates did not differ across arms) 
and analysis was per protocol with high risk of resulting attrition bias.2 
Another 3-arm trial randomized N = 63 chronic subjects (1-22 years post-stroke) 
to computer SLT, computer stimulation, or no SLT. After 26 weeks, the computer SLT 
group had greater improvement on the PICA and WABAQ than the group receiving no 
SLT (p<.001),1 However, analysis was again per protocol. Additionally, while promising, 
the results do not generalize to other treatment approaches or stages post-stroke, and at 22 
years post-stroke, clinical relevance of any therapy is limited. 
The other positive trials used acute study populations, but were underpowered, 
and again, results are specific to their therapeutic interventions. In N = 59 subjects who 
were mean 3.19 (SE 2.2) days post stroke, randomized to intensive SLT with box, 
mapping, and lexical-semantic approaches or usual care (no SLT), the SLT group was 
found to have improved aphasia severity relative to the control (p=.010). Limitations 
include failure to meet pre-specified power and differences across groups at baseline, 
with higher modified Rankin Scores (p=.008) in the usual care group.3 In an RCT pilot 
with N = 12 patients randomized to “intensive SLT” initiated 2 days after stroke or no 
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SLT, the treated group improved more on naming (p=.01) and written language (p=.02) 
than the control group, and this improvement corresponded to a different pattern of 
cortical activation on event-related fMRI.5 Besides the small sample size, one limitation 
of this study is that in order to be capable of performing a task while undergoing fMRI, 
subjects could have at most moderately severe aphasia, and since initial aphasia severity 
is known to predict recovery, 8,12-18 it may be that the skewed aphasia profile of subjects 
influenced outcomes more than the treatment they received. Finally, in an underpowered 
(N = 30) RCT pilot studying sub-acute subjects, MMIT group had greater improvement 
in repetition and responsiveness tests than the untreated control (p=.02),5 but this was 
after a single session of treatment with no longer term follow-up, so it is unknown if a 
similar effect would be seen with more regular therapy or persist over time. 
Two9,10 of the studies finding no significant effect of SLT used small samples (N 
= 24) of chronic subjects( > 1 year9 or > median 30 months10 post-stroke) and a 
Constraint Induced Aphasia Therapy (CIAT) intervention that is a structured and very 
intensive (3h/day for 10 days) group therapy with no generalizability to other therapeutic 
approaches. The three larger trials finding no improvement in outcomes attributable to 
SLT have significant methodological limitations. In (N = 191) sub-acute subjects 
randomized to SLT for 2 hours/week or no SLT, more than 2/3 of SLT patients received 
significantly less than 2 hours of SLT per week,19 and even 2 hours per week is likely an 
insufficient dose to see a response.19-21 Additionally, patients with prior strokes were 
included in the study, obscuring aphasia diagnosis and assessment of recovery. Finally, 
despite randomization at the outset, analysis was per protocol and substantial attrition 
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was handled by essentially selecting a case-control sample to analyze, eliminating the 
benefit of initial randomization.  
The remaining 2 RCTs7,22 that find no effect of SLT are large and adequately 
powered (N = 123 and 152 respectively), but suffer from other limitations. They include 
all aphasia types, relative to most other study populations, global aphasia and Wernicke’s 
aphasia relative were overrepresented, and these aphasia types are known to have 
significantly reduced propensity for recovery.8,12,14 Also both studies used a local 
(country-specific) therapeutic approach for intervention with no external validity, and 
measured outcomes with the Amsterdam-Nijmegen Everyday Language Test (ANELT-
A) “understandability” assessment23, a measure that has been used rarely,7,22,24,25 perhaps 
because it has limited construct validity with variable sub-construct correlation across 
aphasia types (range of r = .27- .66),23 and has been criticized as being “highly 
subjective.”26           
B. Type of Therapy 
 A number of RCTs have compared different types of service delivery and 
theoretical approaches to SLT. Service delivery comparisons of group therapy,27 
volunteer-facilitated therapy in a home setting,2 and computer-based therapy1,28,29 
interventions with “standard” SLP-facilitated therapy controls, have generally identified 
no significant differences in communication outcomes across groups. However, with 
small sample sizes (N = 24 to N = 121 randomized to 3 arms), it may be that differences 
between groups exist but are not statistically detectable. Additionally, these comparisons 
been undertaken in anywhere from one to a small number of trials using heterogeneous 
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communication assessment instruments, outcomes, and elapsed time post-stroke onset; 
the evidence behind any one comparison is sparse. 
 Comparisons of other theoretical approaches to SLT have included local 
approaches with no broader geographic applicability.7,30 Two RCTs compared Cognitive 
Linguistic Therapy with, alternatively, Communicative Therapy25 or no SLT22 and found 
no significant difference between communication outcomes across groups. In trials 
studying specific therapeutic approaches, Constraint Induced Aphasia Therapy 
(CIAT),9,10,31-35 and MIT4,36,37 have been most studied. 
CIAT is an intensive approach that makes use of groups and mass-practice and 
restricts use of compensatory (e.g. nonverbal) communication tactics. Generalizing across 
trials,9,10,31-33 it has not been found to be efficacious.  
 Finally, MIT is a hierarchically structured approach that uses intonation (singing) 
at two pitches that correspond to syllabic emphasis patterns in normal spoken language to 
guide non fluent PWA through 3 levels of increasing phrase length and decreasing 
therapist support.38 Three trials4,36,37 with positive findings now add to case series and 
controlled study evidence39-45  Briefly, while the trials were underpowered (with N = 17, 
27, and 30 respectively), MIT-treated groups were found to have greater improvement in 
communication compared with SLT,36,37 or with no therapy4 in sub-acute populations, 
and this improvement was greater when MIT was initiated earlier rather than later.37 We 
discuss these trials in greater detail below. 
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C. MIT 
a. Proposed Mechanism of Action 
In 1836, Béhir first described a patient who was able to sing la Marseillaise while 
he could speak only the monosyllable ‘tan,” and reports of this clinical phenomenon have 
been common since. In an observational study of 24 patients with Broca’s aphasia and 
underlying left hemispheric lesions, 87.5% had at least some preserved singing ability.46    
Singing maps to bilateral cortical structures that largely overlap the structures that 
underlie speaking, but with greater right lateralized activation of the superior temporal 
gyrus, inferior central operculum, and inferior frontal gyrus in singing than in speaking.47 
Melody is processed predominantly in the right hemisphere ,48,49 and this may account for 
stroke patients’ ability to sing the text of a song which they are unable to speak.47 
MIT was proposed by its originators to use melody to engage the right 
hemisphere to promote speech.50,51 Several functional imaging studies support this 
hypothesis. In a functional magnetic resonance imaging study, 2 subjects matched on 
lesion size, location, and baseline aphasia severity received MIT or a control therapy 
identical to MIT but without intonation or hand tapping, and underwent communication 
assessment and fMRI before and after treatment. The MIT subject was found to have 
greater communication improvement relative to the control, with changes in the right-
hemispheric premotor, inferior frontal, and temporal lobes, while the control-treated 
subject had changes in the left-hemispheric inferior pre- and post-central gyrus and the 
superior temporal gyrus.43 In a Diffusor Tensor Imaging (DTI) study of 6 subjects who 
underwent DTI and behavioral assessments before and after treatment with MIT, a 
significant increase in right hemisphere arcuate fasciculus fibers and volume was found 
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to in parallel improvement on behavioral testing.42 Another larger (N = 20) DTI study 
used a controlled but non-randomized design and found right hemispheric white matter 
changes in the MIT group, but not the control (p < .05), as well as within group 
improvement in behavioral testing only in the MIT group (p < .001).52 However, 
mirroring the broader debate about lateralization in spontaneous recovery, one study of 7 
patients previously treated with thérapie mélodique et rhythmée (TMR, the French 
version of MIT) who underwent positron emission topography (PET) scan while 
performing MIT and control tasks found the opposite pattern: left hemispheric cerebral 
blood flow (CBF) increased on MIT tasks, and right hemispheric CBF increased on 
control tasks. This study has some major limitations and should be interpreted with 
caution: 5 of the 7 patients had global or Wernicke’s aphasia and thus poor candidates for 
MIT, the facilitation techniques used and hypothesized mechanism of action behind TMR 
do not implicate the right hemisphere,53 and most importantly, the imaging is only post-
treatment: it is hard to know whether the task-related CBF changes correspond to residual 
deficits or recovery.54   
 Other imaging studies have tried to isolate the aspect of MIT that might underlie 
efficacy, with a focus on melody versus rhythm. These studies yield equivocal results, 
finding that rhythm alone is associated with improved “articulatory quality,”55  or 
alternatively that “speech informativeness” improved only after treatment with both 
melodic and rhythmic components of MIT.48  
Imaging studies in general suffer from the limitation that the particular task used 
in functional imaging can spuriously impact the lateralization observed. For example, 
formulaic language and spontaneous language lateralize distinctly. 56 Given that even in 
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healthy patients there is a spectrum of lateralization,57 and that hemispheric activation 
varies in spontaneous recovery,58 it is not surprising that there are contradictory findings 
in studies of brain remodeling associated with MIT. Inter-subject variability in time since 
stroke, lesion size and location, and environmental and genetic factors, may also 
confound findings, and case studies cannot control for patient selection. Moreover, the 
imaging studies employ chronic patients who have previously received SLT to which 
they have been refractory, and without comparing randomized treatment and control 
groups, it is difficult to know whether communication performance and imaging findings 
issue from MIT, spontaneous recovery, or some other source. 
b. Efficacy 
 The American Academy of Neurology has rated MIT as “promising” for Broca’s 
aphasia, with support from class III (expert opinion and case based) evidence.59 To our 
knowledge, no completed trial to date has established efficacy of MIT, however results 
from existing MIT trials are promising, with significantly positive outcomes in MIT-
treated groups relative to groups receiving control treatment. 
In the first period of an RCT using a crossover design (further discussed in the 
section 2.2(D) on timing of therapy below), 27 sub-acute (2-3 months post stroke) 
subjects were randomized to receive 6 weeks of MIT for 5 hours/week or an equivalent 
volume of SLT focused on non-oral communication and were assessed at baseline and 6 
weeks with the Aaschen Aphasia Test (AAT) repetition and naming sub-tests60, 
ANELT23, and Sabadel story retelling task and an MIT repetition. In ITT analysis, the 
MIT treated group improved more than the SLT treated on the MIT trained repetition task 
(beta = 18.3, p< .01) and AAT repetition sub-section (beta = 17.2 p <.05). The two 
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groups were comparable at baseline, except for gender (χ2 = 4.03, p=.045), but gender 
has been found elsewhere to have no independent association with aphasia recovery 
elsewhere,8,12,13,15-17 and gender and initial aphasia severity were both included in 
regression analysis, eliminating concern for confounding. Further support for MIT comes 
from within group improvement (p<.01) in the MIT group on all but the Sabadel, with no 
corresponding within group improvement seen in the control group. Adherence, 
measured by intensity of actually received therapy did not differ across groups (p=.49) 
and exceeded pre-specified minimums.37 One limitation of this study is the lack of longer 
term follow-up to establish the persistence of response to treatment. Additionally, the 
study used the original MIT protocol,50,51 but the study authors question whether a 
modified version might have had greater effect.37 The main limitation of this study, 
however, is that it was powered to find an effect on the Sabadel, non-standard test, that 
may be poorly suited to the non-fluent study population.37 Four patients withdrew from 
MIT within 2 weeks, resulting in inadequate power. Looking at standard errors, we can 
see high variance in the sampling distribution of between group communication changes, 
and this may have inflated the estimated effect size. Regardless of power, this trial cannot 
establish MIT efficacy because the control consists of SLT, rather than no treatment. 
However, the control treatment approach deliberately avoids spoken elements, so it 
comes closer to approximating no SLT than many other alternate therapeutic approaches 
when compared with MIT. Despite inadequate power, the positive finding and its 
robustness in a second period after crossover (see section 2.3(C) below), strongly 
motivates additional RCTs to establish efficacy of MIT. 
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 The same authors use the same study design in an RCT pilot, but with a chronic 
population (mean 33.1 [MIT] to 42.6 [control] months since stroke, difference not 
significant, p =.54), and with a control of no SLT, reflecting common practice in such 
chronic patients. In principle this control would allow identification of efficacy, however, 
recruitment was limited by difficulty in finding subjects able to agree to the logistics of 
treatment, and at N = 17, the study was underpowered, with no significant differences 
between groups found on any outcome measures.36 The lack of effect may reflect the 
high variance in this small sample (standard errors are more than 1/2 the means and 
within group differences in means show some a mix of expected and counter-intuitive 
patterns), or alternatively, it may be that MIT indeed has no efficacy so long after stroke. 
This study in no way reduces motivation to establish efficacy of MIT in an acute 
population since this study population is so far outside the time window in which patients 
would ever receive treatment. If anything, juxtaposed with the authors’ positive findings 
in a sub-acute population, this study lends further support to exploration of initiation of 
MIT as early as practicable after stroke. 
 Finally, an RCT pilot4 compared a MMIT intervention with a no SLT control in 
the first weeks after stroke, and while with N = 30, it too is underpowered, it found an 
immediate benefit to MMIT after one brief session, further underscoring the need for an 
adequately powered RCT to study the efficacy of a longer regimen of MIT during the 
acute stage post-stroke. The study setting was an inpatient stroke unit, and 90% and the 
study population was sub-acute with 90% of patients within 13 days of stroke at the time 
of intervention. Five sessions of MMIT (intervention) or SLP visit with no SLT (control), 
with a responsiveness and repetition assessment designed for the study by neurologists 
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and SLPs administered immediately following sessions. Comparing MMIT with control, 
the MMIT group improved more after the first session (p=.02), and also showed within 
group improvement (p=.02), while the control did not (p=.73). The two groups were 
comparable at baseline, and post-hoc analysis ruled-out any training effects. The major 
limitation of this study is that due to scheduling difficulties in the stroke unit, no subjects 
completed the planned 5 sessions, and only 17 of 30 completed the 2nd session 
assessment. As a result, degrees of freedom were insufficient to compare outcomes 
beyond the first session. While the control of no SLT provides the right comparator to 
establish efficacy, it seems highly unlikely to do so based on a single successful session, 
particularly as patients had no longer term follow-up so it is unknown if the treatment 
effect persisted beyond the immediate term. Another significant drawback of this study is 
the use of an unvalidated, custom-designed aphasia assessment instrument. Nonetheless, 
these findings suggest a need for a larger RCT to compare early MIT with no SLT using 
a longer and more intensive MMIT intervention that spans inpatient and outpatient 
settings, and where aphasia severity is assessed with a validated instrument. 
D. Timing of Therapy 
 Given that spontaneous recovery occurs at an attenuating rate over time and is 
associated with patterns of cortical re-organization, the timing of SLT likely affects its 
efficacy. In principle, therapy initiated earlier that coincides with a period of enhanced 
neuroplasticity could provide synergy and result in greater recovery than would be 
feasible relative to spontaneous recovery alone, or the same therapy initiated later time 
when cortical re-organization is minimal. Nonetheless, the optimal timing of SLT for 
post-stroke aphasia remains an open question. While RCTs have initiated interventions as 
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early as 2 days5 and as late as 29 years21 post-stroke, only two21,61 have directly compared 
earlier with later initiation of therapy. A meta-analysis of 55 studies found a greater 
treatment effect (Cohen’s d = .61) when therapy was initiated within 3 months of stroke, 
than when it was initiated later (Cohen’s d = .31). However, the majority of RCTs have 
been conducted in chronic populations, often one to many year post-
stroke,1,9,10,24,26,28,31,36,42,43,54,62,63 a time period when insurance reimbursement has been 
exhausted64 and is therefore not clinically relevant. A growing body of RCTs has initiated 
interventions in sub-acute4,22,25,29,30,32,65 or acute3,5,7 study populations, but without 
directly comparing early and deferred therapy, it is impossible to infer causality between 
early treatment and better outcomes because the observed association may reflect 
selection bias if patients who can tolerate earlier treatment also recover better. 
Two RCTs2,37 have directly compared earlier with later initiation of therapy and 
obtained orthogonal results, which must be interpreted conditionally on their 
interventions. One of the comparisons in a 3-arm RCT with total N = 121 sub-acute 
subjects is between 12 weeks of SLT for 8-10 hours/week and the same SLT initiated 12 
weeks later. At 12 weeks, aphasia (as measured with PICA11) improved more in the 
group receiving SLT than the deferred SLT group (P<.05), but at 24 there was no 
difference (p>.05) between groups, suggesting no disadvantage to deferring SLT. 
However, per protocol analysis was based on 94 subjects who completed the. 
Additionally, it may have been difficult to detect a difference from deferring SLT in this 
study because the interval of deferral was short enough that both groups began and 
completed therapy during the sub-acute stage when spontaneous recovery pervasive and 
less variable.66 The other trial (discussed at length in section 2.2(C) above) directly 
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comparing earlier and later treatment used a double crossover design with MIT and SLT 
interventions in sub-acute patients subjects. In ITT analysis with repeated measures 
ANOVA, the group receiving MIT in the first 6 weeks improved more on a repetition 
task than the group receiving MIT in the second 6 weeks (F = 8.89, p=.001).37 
Additionally, in a secondary analysis, time post-stroke was one of the only significant 
predictors of communication improvement (p< .05 on ATT repetition60, ANELT23, and 
MIT repetition), with greater communication improvement associated with shorter time 
since stroke. While attrition led to inadequate power, these findings suggest that at least 
in the case of MIT, earlier initiation of therapy may be more beneficial. 
 Finally, as there are some parallels between patterns of spontaneous recovery in 
speech and motor function,15 it is worth noting that an RCT comparing earlier (3-9 
months post-stroke) and later (15-21 months post stroke) motor therapy found greater 
improvement in the group starting therapy earlier.61  
E. Very Early Therapy 
While the optimal timing of therapy remains an open question whose answer may 
depend on therapeutic approach, recent trials have established the feasibility of starting 
therapy as soon as 2 days post-stroke. One of the largest (N = 123) trials in the SLT 
literature initiated its “Language Enrichment Therapy” intervention or no SLT at 3 days 
post-stroke. While there was no difference between groups on communication 
assessments at 3 weeks or 6 months, this may be due to limitations including the 
idiosyncratic intervention, a sample with overrepresentation of unresponsive aphasia 
types, and use of assessment instruments with weak psychometric properties. Regardless 
of findings, this study met pre-specified power thresholds with 93% of subjects 
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completing the primary endpoint, and 80% of subjects completing follow-up, in both 
experimental and control groups, and all subjects in the SLT group tolerated the planned 
volume of SLT,7  showing the feasibility of recruiting a large sample and starting an 
intensive SLT intervention 3 days after stroke. Two smaller RCT pilots3,5 that initiated 
therapy within 3 days of stroke did find significant communication improvement in the 
groups receiving intensive SLT compared with the controls receiving no SLT. While the 
efficacy of therapy initiated within days of stroke remains to be established, its 
practicality and feasibility is clear.  
F. Intensity of Therapy 
 While intensity of therapy has been studied, there is no universal definition of 
what constitutes intense treatment. RCTs have evaluated “Intense” interventions 
consisting of 5-7 days/week of SLT in 45 minute3,7 60 minute5,22,65 or 2 hour24,29,30 
sessions. Two meta-analyses older trials provide benchmarks that are often cited: 
interventions with at least 2 hours/ week of SLT resulted in a doubling of Cohen’s d,20 
while a minimum of 8.8 hours/week of SLT was needed to obtain significant 
improvement in PICA scores.19 Intensity has also been studied indirectly by using an 
inherently intense structured treatment like MIT36,37 or CIAT,10,31,62  but findings do not 
generalize beyond these therapeutic approaches. 
RCTs explicitly comparing higher and lower intensity treatment have yielded 
mixed results that vary across timing post-stroke (in an acute3 and chronic24 population, 
greater intensity was found to be beneficial , while in sub-acute populations29,30,65 it was 
not) and therapeutic approach (e.g. CIAT,31 multi-modal stimulation,30 computer 
therapy29). Even without considering threats to internal validity, their results are specific 
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to the parameters of their interventions and do not generalize. Compared with other SLT 
trials, intensity trials have more often found differences between groups at baseline3,24,29 
and high drop-out rates.3,30 Additionally, in a trial finding no difference between intense 
and standard (5 vs 2 hours/week) SLT,65 adherence was a problem, so the differential 
between intensities of SLT actually received was narrow, and making it harder to find a 
significant effect. However, in this trial, comparing outcomes with a third group 
receiving standard SLT delivered by the National Health Service (NHS), the NHS group 
(mean) .57 hours/week SLT improved less than the non-NHS standard SLT group (mean) 
1.6 hours/week SLT suggesting that some minimal dose threshold may be needed to see 
any treatment effect.  
2.3. Review of Relevant Methods 
A. Study Design 
The proposed study will be a multi-center22,24,36,37 randomized, controlled trial to 
compare aphasia recovery across patients receiving MMIT4 or usual care during a 3-week 
period that begins 3 days post-stroke. Randomization will be centrally accomplished 
using computer generated random number sequences and sealed envelopes.7,22,24,30,33,36,37 
Permuted blocks24,29 will be used to maximize power via balanced (1:1) allocation of 
subjects to intervention and control groups.67 Block sizes will be randomly distributed 
across even numbers between 2 and 6 to further ensure that researchers are blinded to 
subject assignments.67-69 
B. Patient Selection 
 Inclusion and exclusion criteria vary considerably across SLT trials. Within the 
bounds of what is well-supported by multiple prior studies, our general approach will be 
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to keep inclusion criteria broad and exclusion criteria minimal to rapidly meet and exceed 
our pre-specified sample size and power.70 
Eligible patients must be admitted to one of our participating VA Primary Stroke 
Centers (PSCs) with radiologically confirmed diagnosis of acute stroke, conforming to 
the World Health Organization definition71 on CT or MRI3,9,10. Both ischemic and 
hemorrhagic strokes will be included.3,22,24,65,72 Beyond requiring that subjects be  ≥18 
years of age,4 we will impose no upper age limit on our sample.6 Given the difficulty in 
interpreting disorders of higher cerebral function when there has been has been prior 
stroke,16 we will include only patients with first-ever stroke,2,4,7,10,22,27,33,65,73 Participants 
must be able to react to verbal commands, but need not be fully alert74 (consistent with a 
Glasgow Coma Scale (GCS) score > 10).3 Patients who are unstable and require transfer 
to ICU, with concurrent ACS or acute heart failure, or who require hospice care will be 
excluded.74 We will also exclude patients with prior neurological or communication 
disorders,5,33 severe dementia,3,7,10,22,30 severe depression,5,10,65 significant 
hearing/sensory deficit1-3,24,27,28,33,36,37,75 or who are unable to consent or undergo 
treatment. Patients must be native or primary English speakers.3,4,22,36,37 
We will employ a few inclusion criteria targeted at recruiting good candidates for 
our MIT intervention, since different aphasia and lesion types have different propensity 
to respond to this therapy. In the original MIT protocol, ideal candidates were described 
as patients with unilateral left-sided lesions, and non-fluent aphasia with poor repetition 
and articulated speech but relatively well-preserved comprehension,51,76 and an early CT 
lesion study (N = 8) found that successful MIT patients had frontotemporal lesions 
extending into less than half of Wernicke’s region or the subcortical temporal isthmus.35 
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Accordingly, we will include patients with left-sided lesions2,4,10,27,28,30,33,36,37,75 and we 
will exclude those with right sided or bi-hemispheric lesions.36,37  
Patients with Broca’s aphasia are considered the most ideal candidates for MIT, 
while patients with Wernicke’s or global aphasia are considered the least ideal aphasia 
types for this therapy.59 Given our acute study population and short timeline, it is not 
practical to formally classify aphasia type prior to enrollment, but VA/DoD acute stroke 
treatment algorithms77 require that acute stroke patients be screened within 24 hours 
using the National Institutes of Health Stroke Scale (NIHSS),78 the most commonly used 
global disability assessment in the U.S. with excellent psychometric peroperties78-80 We 
will include patients with an NIHSS language score of 1 or 2, thereby effectively 
excluding those with global aphasia or no impairment.4 
C. Clinical Management 
From hospital admission until the sooner of hospital discharge or the end of the 3 
week experimental period, the primary team responsible for the patient will provide 
supportive care and monitor for stroke complications according to ASA guidelines.81 
Following discharge, there will be no need for incremental monitoring beyond what is 
determined by the primary team. The American Academy of Neurology considers MIT to 
be safe and without risk.59 
D. Intervention 
 Several case and imaging studies35,42-45 as well as the RCTs comparing MIT with 
SLT in sub-acute and chronic populations 36,37adhered strictly to the original MIT 
protocol51 in designing their intervention. However, the authors of the RCTs cite this as a 
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limitation and speculate that adaptation of the original MIT could yield better 
outcomes.36,37 
In addition to being very structured and hierarchical, the original MIT protocol51 
is very intensive, with an expected 75 – 90 sessions delivered over a limited period of 
(ideally) 3-6 weeks,59 making it impractical in some patients and settings.4,34 The 
originators of MIT51 have thus endorsed MITs adaptation to meet individual patient needs 
or insurance constraints and this has become common in clinical practice. The adaptation 
of MIT has also extended into the scientific literature, with several formally described 
variations including “Modified MIT,”82,83 TMR,41,53 and “Palliative MIT”.53  
In our study, we will use the MMIT83 described in Conklyn et al. 2012,4 the MIT 
pilot RCT whose study setting and population most closely resembles ours. In this 
intervention, SLP has autonomy to advance the patient through the phases of MIT faster 
than dictated in the original protocol, and therapy is delivered in 15 minute increments.4 
As is the norm in scientific study and clinical practice, the precise content of intervention 
sessions will be determined by the SLP according to individual patient profile on an 
individually appropriate basis.2,6,21,64,84 Generalizing, an SLP will begin by teaching the 
patient a single melodic phrase assisted by rhythmic tapping with the left hand. Over the 
course of subsequent sessions, the SLP will use patient success to guide timing of 
progression to additional and progressively longer melodic phrases, with an ultimate 
transition to using less intonation to closer approximate speaking. Following the literature 
on very early SLT,3,5,7 the dose of our MMIT intervention will be a total of 45 minutes 
per day, 5 days per week, over the 3-week experimental period, and the 45 minutes per 
day may be accomplished through three time-spaced sessions.7,22 
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While MIT is considered to be safe,59 it is worth noting that a phase II trial 
comparing “higher dose” of early (within 24 hours of stroke) mobilization with usual 
care, found no difference in mortality across groups (p=.20), and as very early 
mobilization has higher risk than early MIT, this reassures us that our intervention will be 
safe.74 
E. Control 
 Our control consists of “usual care” in the first 3 weeks following stroke: a 
swallow screening,81,85,86 a formal speech assessment by an SLP that makes use of a 
standardized instrument,87 and if appropriate, referral for subsequent outpatient 
therapy.88,89 Formal SLT is not a part of usual care during this period.  
F. Primary Outcome 
 The majority of SLT trials have looked for differences in overall aphasia severity 
across groups, using language batteries to quantify receptive and expressive language. 
The oldest trials2,6,27 used the PICA,11 whose validity has not withstood empirical 
interrogation.90,91 The many SLT trials undertaken in non-English speaking countries 
have often used assessments designed in their local language, although translated and 
validated versions of at least the WAB do exist.12,39 Trials in German speaking countries 
have overwhelmingly used the “standard” German assessment, the AAT,5,31-33,36,37,62,63 
while a few Nordic trials7,22,24,25 have used the ANELT23, which as we noted above, has 
limited construct validity,23 has been criticized as being “highly subjective”,26 and does 
not measure aphasia severity.  
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The most commonly used assessment in RCTs conducted in English-speaking 
countries is the Western Aphasia Battery (WAB),1,3,4,28,29,39,65,72,92 which has also 
dominated the case and observational literature on aphasia.12,14-16,39,92-96 
 As we will recruit sites from VAMCs, we adhere to the VA/DoD 
recommendation77 to use one of the Agency for Health Care Policy and Research 
(AHCPR) preferred instruments: PICA11, Boston Diagnostic Aphasia Exam (BDAE)97, or 
WAB98.  
In our RCT, we will use the WAB to assess aphasia severity because it is used 
extensively in clinical practice, and almost to the exclusion of all other instruments in 
English-language SLT trials. According to a survey of clinicians treating aphasia in 
English speaking countries, the WAB is the second most employed assessment.64 The 
WAB has rigorously tested psychometric properties. It is superior at classifying aphasia 
types,99 and it has high internal consistency, test re-test reliability, inter-rater reliability, 
content and construct validity, and discriminant validity.94,100-103 In a small sample (N = 
10), depending on the cut-off employed, the sensitivity of the WAB ranged from 60 – 
80% while the specificity ranged from 100 – 80%.102As importantly, the WAB correlates 
with functional outcomes.73,95 Specifically, we will use the Aphasia Quotient (AQ) 
score,98 a weighted average of all spoken language subtests (spontaneous speech, 
auditory verbal, naming, and repetition) that has been used elsewhere1,3,28,29,65 to measure 
aphasia severity (see Appendix E).98  
  Our primary outcome will be the mean difference from baseline across MMIT and 
usual care groups in change in aphasia severity as measured by the WAB-AQ after 3 
weeks.  
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G. Secondary Outcomes 
 The effects of MIT have found to be stable for a 3 month period after completion 
of therapy.104 As we want to know if any treatment effect of MIT endures, we will 
continue to follow patients after the 3-week experimental period, with final WAB-AQ 
assessment at 6 months post-stroke. This corresponds to the follow-up period commonly 
used in other trials1,3,5-7,22,24,65 and also encompasses the period during which spontaneous 
recovery is known to be maximal.13,16,17,66,93,105,106 Our secondary outcome will be the 
mean difference across MMIT and usual care groups in change in aphasia severity as 
measured by the WAB-AQ after 3 weeks. 
H. Sample Size 
 Our study will be powered to detect a statistically and clinically significant 
difference in primary outcomes across our intervention and control groups, and ex ante 
power calculation will determine our sample size. To establish the target effect size, we 
reviewed RCTs,3,4,28,30,37,65 a controlled study,39 and an outcomes study95 that used an 
MIT intervention, the WAB assessment, or both. As aphasia recovery varies over 
time13,16,17,66,93,105,106and treatment effects may vary with dose,19-21 we will adopt the 
effect size of Godecke et al. 2012,3 who finds a WAB-AQ difference of (mean) 15.1 
points (p=.010) in SLT versus usual care groups. While this SLT intervention differs 
from our MMIT intervention, the acuity of our study population and the timing and dose 
of intervention are closely approximated. Since no single therapeutic approach has been 
shown to be superior to any other,21 and MIT has more positive evidence 4,36,37 34,35,40-
44,50,51,107 behind it than most other approaches, if anything, the 15.1 point effect should 
be a lower bound for us. Moreover, 15.1 was the effect size identified after controlling for 
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initial aphasia severity with Generalized Estimating Equations (GEE), and while we will 
control for initial aphasia severity with multivariate regression in our secondary analysis, 
our primary outcome is a simple difference in difference, again suggesting that 15.1 is the 
lower bound on the treatment effect we should seek to detect. Using a lower bound on 
effect size to parameterize our sample size calculation is desirable, since effect size and 
sample size vary inversely.  
However, as Godecke et al. 20123 did not report their standard deviation, we 
obtain our standard deviation parameter value from Bakheit et al. 2007.65 In this study, 
assessment with the WAB-AQ occurred at regular 4 week intervals, so we compute the 
standard deviation of the between group difference after 4 weeks of intervention using 
the within group values in table 7 (see Appendix F for details on this computation). This 
yields a standard deviation of 17.71, which we will use with the effect size of 15.1 to 
determine the sample size needed to achieve 80% power and .05 significance with a two-
sided hypothesis. 
I. Estimated Recruitment Sites 
We will recruit sites from the self-designated108 Primary Stroke Centers (PSCs)   
of the Veteran’s Administration Medical Centers (VAMCs). In 2016, there were a total of 
7,616 acute stroke hospitalizations across VAMCs.109 The VAMCs constitute the largest 
healthcare system under single management structure in the United States,64,108 and offer 
consistent care, service delivery, and treatment coverage to their beneficiaries. Moreover, 
algorithms issued in the VA/DoD evidence-based stroke rehabilitation guidelines77 
enhance consistency in treatment approach across VAMC providers and staff. Perhaps for 
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these reasons, the VAMCs have been the dominant sites of scientific study of SLT for 
post-stroke aphasia in the United States.2,27,66,103,110 
Based on the midpoint of findings in the epidemiological literature, we expect that 
31% of acute stroke patients will be aphasic on initial screening and thus eligible for our 
study.8,13,14,93,111-115 Additionally, averaging completion rates of 76.5% (Godecke et al. 
2012) and 44.7% in (Bakheit et al. 2007), the studies from which we derive effect size 
and standard deviation, we estimate that 61% of patients identified as eligible by the 
primary team will complete the study to primary endpoint.3,65 
We will use the aphasia rate and study completion rate to scale our estimate of the 
number of sites needed to obtain our sample size. 
J. Confounding 
 The randomization process should yield MMIT and usual care groups that are 
comparable at baseline,67 and thus decrease the risk of confounding of the relationship 
between MIT and aphasia recovery. We will collect data on patient and stroke 
characteristics whose influence on recovery has been studied to assess the comparability 
of our groups, and we will include these in a multivariate regression as part of our 
secondary analysis as an extra safeguard against potential confounding. 
 Among the unmodifiable characteristics that have been studied, initial aphasia 
severity has consistently8,12-18 been found to predict subsequent aphasia recovery, with 
greater initial severity associated with lesser subsequent recovery, and moreover, initial 
severity has a great deal of predictive power: 81% of the variance in aphasia difference 
from baseline after 3 months was explained by initial severity in a multivariate regression 
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of N = 21 patients with mild to moderate aphasia, and this relationship persisted for 
patients who did (R2=0.76, P=0.005) and did not (R2=0.90, P=0.001) receive SLT.15  
There is some evidence that aphasia recovery can vary with aphasia type, with 
global aphasia and anomic aphasia having lower rates of recovery.14,96,105 On the other 
hand, most evidence finds no gender8,12,13,15-17 age difference13,15-17,96,116 or educational 
attainment16 in aphasia recovery, although one study found that younger patients showed 
greater recovery over 18 months.8 Lesion size and location are established clinical 
predictors of aphasia type,12,13,110,115,117,118; however, in multivariate analysis, lesion size 
did not predict aphasia recovery after controlling for initial aphasia severeity.16 While 
left-handed patients may have greater right-sided lateralization, handedness did not show 
an independent association with degree or likelihood of aphasia recovery.13,117    
K. Conclusion 
 The efficacy of SLT generally and any specific therapeutic approach remains to 
be established, and its study has been constrained by ethical considerations that preclude 
use of a control with no therapy in the sub-acute and chronic study populations that have 
dominated the literature. MIT is well supported by case, imaging, and pilot RCT evidence, 
but its efficacy has yet to be established in an adequately powered RCT. Recent studies 
have explored starting MIT earlier than has been done in older studies, and have 
concluded that this is both beneficial and feasible. 
 Neuroimaging data tell us that the greatest potential for aphasia recovery occurs 
during the first days to months following stroke during which right hemisphere cortical 
structures are recruited to promote speech while affected homologous left hemispheric 
structures recover. MIT is hypothesized to work by using melody, processed in the right 
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hemisphere, to promote speech in non-fluent PWA, and this has some support in 
neuroimaging data. From a pathophysiological perspective, very early therapy could 
perhaps harness cortical activation patterns that are already observed in spontaneous 
recovery to induce greater therapeutic response, and this is particularly true in MIT with 
its proposed patterns of lateralization. 
 While the acute, inpatient population has historically been understudied, several 
trials including one of the largest SLT trials, have now established the feasibility of 
initiating therapy, including MMIT, as early as 3 days post-stroke. There are strong 
reasons to target this population in future RCTs with an MMIT intervention.  
In addition to pathophysiologic motivation to study an early intervention, 
studying an acute patient population would allow ethical comparison of therapy with 
usual care involving no formal therapy, since this population does not typically receive 
therapy, the comparison we need to establish efficacy.  
 For these reasons, we propose an RCT to compare MMIT with usual care, 
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CHAPTER 3: STUDY METHODS 
 
3.1 Study Design 
The proposed study will be a multi-center two arm prospective, randomized, 
parallel group, open-label, blinded endpoint assessment (PROBE) trial.  
3.2 Study Population and Sampling 
 The population will consist of men and women ages 18 and older with a diagnosis 
of acute stroke and communication impairment (NIHSS score of 1 or 2) within 24 hours 
of presentation to a participating VAMC PSC. Eligible subjects who meet inclusion 
criteria but no exclusion criteria (Table 1) and have given consent, confirmed by a 
physician or midlevel provider, will be enrolled consecutively as they present. Sampling  
will occur over 18 months to commence on the start date of the study. 
Table 1: Eligibility Criteria 
Inclusion 
Age >= 18 
First ever acute stroke, radiologically confirmed (CT or MRI) 
Left sided lesion 
NIHSS language score of 1 or 2 within 24 hours of admission 
Able to react to verbal commands (need not be fully alert) 
Native/ primary English speaker 
Able to consent/ undergo treatment 
Exclusion 
Requiring ICU transfer or hospice care  
Concurrent ACS or decompensated heart failure 
Right sided or bi-hemispheric lesion 
Prior stroke, lesions, neurological or communication disorders, severe dementia, severe 
depression 
Uncorrectable hearing deficit 
Prior exposure to MIT 





3.3 Procedures and Recruitment 
 Eligible VAMC PSCs will be approached in order of their stroke volume ranked 
from greatest to lowest to satisfy the required sample size estimated below. A letter 
(Appendix B) with a description of the study will be sent to service chiefs in appropriate 
clinical service lines (e.g., Neurology) and union leadership for permission to approach 
VAMC employees to discuss the project. The Medical Director of participating VAMC 
PSCs will be contacted by letter to inform them of the study. Participating providers will 
be asked for their help in enrolling eligible patients in this study. We will follow-up to 
answer questions by phone.  
 Each site that agrees to participate will be assigned a research assistant who will 
provide information to participating clinicians and subjects, assist with identification and 
enrollment of patients who meet study inclusion and exclusion criteria. Research 
assistants will also obtain in person subject consent and communicate with the central 
study coordination center about subject group assignments. 
3.4 Subject Protection and Confidentiality 
Prior to the start date of the study, we will obtain VA Central Institutional Review 
Board (IRB) as well as the IRB or Human Subjects Subcommittee (HSS) at each 
participating VA site, as well as the IRB and Human Investigation Committee at Yale 
University. All subjects who will participate in the study will give written informed 
consent (Appendix C). The informed consent form includes a description of the study, the 
duration of participation, potential risks and benefits of the study, alternative options for 
treatment. The form explains that participation in the study is voluntary. Since we will 
only be enrolling English speaking patients in the study, we will only use an English 
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language version of the consent form. If the patient cannot read the form, an oral 
presentation can be given explaining informed consent. A third-party must be present to 
ensure that no information is withheld if the consent form is read to the patient. Given 
that study participants may not have the capacity to comprehend consent or may be 
unable to communicate understanding of consent due to the extent of their injuries, a 
legally authorized representative can consent on the behalf of the individual. We will 
make every attempt to enroll patients that can provide their own consent. The patient or 
representative will be given time to read over and ask questions about the consent form 
prior to signing. The consent form will also authorize the research team to access the 
individual’s protected health information (PHI) and will explain the intended uses of the 
PHI and length of time in which the PHI is needed.  
  In order to maintain confidentiality, the study protocol will be in accordance with 
the Health Insurance Portability and Accountability Act (HIPAA). Only pertinent health 
information will be collected and all patient information used during the study will be 
considered strictly confidential. Only authorized individuals will have access to PHI and 
all members of the research team must complete a privacy-training course prior to 
handling PHI. Each study participant will be assigned a unique ID number and all data 
related to the patient will be labeled with this ID number in order to de-identify the 
patient. All extracted data from patient charts, and assessments will be logged into a VA 
Research Electronic Data Capture (REDCap) database. This REDCap database will only 
store the unique identifiers that are not based on personally identifiable information. A 
separate Cross-walk Excel file will be kept by the research assistant containing the 
unique identifier and personally identifiable information. This Excel file will be password 
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protected and will be saved behind the VA firewall. All paper files related to the study 
will be stored in a secure location in a locked file cabinet accessible only to study 
personnel who must access these files. All PHI will be kept for the duration of the study 
and then will be disposed of in a secure manner.    
3.5 Study Variables and Measures 
Dependent Variable: The dependent variable is the change in aphasia severity at 3 weeks, 
measured by the WAB-AQ. 
Independent Variable: The independent variable is the treatment arm to which the patient 
is assigned: MMIT or usual care. 
Other Descriptive Measures: Additional variables (Table 2) will be used to assess the 
quality of randomization by comparing intervention and control groups at baseline, 
during the 3-week experimental period, and during the extended follow-up period. 
Baseline characteristics that are known to be independently associated with the dependent 
variable, as well as any variables that are found to vary systematically across groups, will 
be used as controls in secondary analysis. Treatment course and follow-up variables will 
be used to analyze secondary outcomes. 
Table 2: Other Descriptive Measures 
Patient Characteristics  
age, education (last grade completed), gender, handedness, active comorbidities, date 
of death (if applicable) 
Stroke Characteristics  
date of admission, stroke type (ischemic v hemorrhagic), thrombolysis, initial stroke 
severity (NIHSS score), lesion site, lesion size, baseline aphasia severity (WAB-AQ) at 
initiation of intervention, length of hospital stay  
Therapy Characteristics for 3-week experimental phase and post-experimental 
follow-up phase  
date of initial and final therapy sessions, hours of therapy completed, number of 
sessions, hours of homework completed, hours of other (non-speech) rehabilitation 
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3.6 Methodological Considerations 
A. Description of Intervention, Control, and Follow-up 
MMIT rehabilitation will be delivered to patients in the intervention group by a 
set of board certified designated SLPs engaged for this study who have agreed to 
delivering therapy according to the specific study protocol only to patients to whom they 
are assigned. Patients will undergo WAB assessment by an independent, blinded assessor 
just prior to starting MMIT. Patients will receive a total of 45 minutes of therapy per day, 
5 days per week, for 3 weeks to start 3 days post-stroke after baseline communication 
assessment that day. The therapy may be delivered in 15-minute increments that need not 
be continuous. Content of MMIT will follow the procedure outlined in Conklyn et al. 
2012: Patients and SLTs will sing short phrases together while tapping rhythm with the 
left hand. The first phrase will be short and used commonly in daily-life (“I need 
coffee”). The therapist will decide at what points to introduce additional phrases, which 
will become longer, more complex, and less frequently used in daily life. Patients will 
undergo repeat WAB assessment by an independent, blinded assessor at the completion 
of the 3-week period.  
Usual care, to be received by all patients, will consist of 1) a swallow screening 
conducted by the primary team within 24 hours of admission and prior to starting oral 
intake; 2) formal communication evaluation conducted by an SLP prior to discharge to 
include communication impairment assessment with the WAB and assessment of 
environment and impact of speech impairment on activity and participation; 3) patient 
and family education conducted by SLP; 4) Referral to and scheduling of SLT 
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(depending on individual patient needs and capabilities) to begin after the 3-week 
experimental phase in standard VAMC venues. 
In the follow-up period, all patients may elect to receive SLT with standard but 
individually adapted parameters. SLPs who treat patients during this period will be asked 
to log time spent in formal sessions and homework. The duration of SLT will vary, but all 
patients will receive follow-up WAB assessment by an independent, blinded outcome 
assessor at 6 months post-stroke. Table 3 summarizes the intervention and assessment 
schedule. 




24h  3 days 
3 weeks + 
3 days 6 months 
  
post-







NIHSS + other 
screening/eligibility X1     
Consent  X1, X2    
Randomization  X1, X2    
Demographics  X1, X2    
Medical history  X1, X2    
Swallow screening  X1    
WAB assessment   X3 X3 X3 
MMIT starts and 
recording of therapy   X4   
Patient diary provided    X5  
SLT starts and 
recording of therapy       X5   
      
X1 = primary team; X2 = research assistant; X3 = trial designated blinded assessor; 
X4 = trial designated SLP; X5 = VA SLP 
(a) secondary outcome      
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B. Randomization Procedure and Assignment of Intervention 
Randomization will be centralized. At each site, as patients are enrolled, a site-
specific research assistant will contact the study coordination center with patient 
numerical IDs. A centralized independent research assistant, not involved in any 
participating site or other aspects of the study, will use a computer-generated 
randomization sequence to assign patient numerical IDs 1:1 to MMIT versus usual care 
groups using permutated blocks of (random) size 2, 4, or 6. Results will be placed in 
consecutively numbered sealed envelopes. The central research assistant will 
communicate patients’ randomization arms to the local IRBs. Site-specific research 
assistants will ensure that the patient is randomized to her assigned group.  
At each site, VA administrative staff who will not be involved in treatment will 
ensure scheduling of MMIT therapy sessions in hospital and outpatient settings and 
ensure that each patient is treated by a single SLP regardless of setting. Staff will also 
schedule communication assessments with independent assessors who have no 
therapeutic role, at 3 days post-stroke, the conclusion of the 3-week experimental period, 
and 6 months post-stroke.  
C. Blinding 
 
While it is impossible to blind patients or SLPs to their treatment, their allocation 
will have been concealed and performed by an independent research assistant as 
described above. Over the course of their 3 weeks, patients in the MMIT group will be 
treated by a single dedicated SLP chosen from a pool of SLPs with comparable 
experience. Outcome assessment will be performed by separate independent assessors 
who are blinded to the patient’s group, baseline characteristics, stroke characteristics, and 
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previous assessment scores. Each site will have 3 independent blinded assessors engaged 
for this purpose. Patients will be asked not to communicate the details of their treatment 
to outcome assessors. Finally, statistical analysis will be conducted at the study 
coordination center by an independent central researcher who is blinded to patient group 
assignments. 
D. Adherence 
 Clinicians participating in the study will be encouraged to adhere to protocol in 
regular check-ins with site specific research assistants. Patients will receive reminder 
phone calls prior to each treatment or assessment session at their primary contact number.  
Patient adherence to assigned treatment will be monitored during the experimental 
phase: SLPs who administer MMIT will log date, duration, and clinical notes for each 
session using the Veterans Health Information System and Technology Architecture 
(VistA) Electronic Health Record (in use since 1981). During this phase, therapy will be 
limited to in-person SLP-administered sessions. After the 3-week experimental phase and 
until follow-up communication assessment at 6 months post-stroke, patients will receive 
variable, individually tailored SLT, and the treating SLPs will be asked to log dates, 
duration, and clinical notes in VistA for each session. During this time period, patients 
may be given homework assignments, and they/their family will be given a diary and 
asked to log dates and time spent on homework.  
3.7 Data Collection 
 Data collection will be completed within 2 years of the study start date, including 
18 months for recruitment and 6 months for treatment and final assessment of the last 
recruited subjects. Baseline patient characteristics, stroke characteristics, and relevant 
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hospitalization and therapy dates are available in VistA. As described above, members of 
the multi-disciplinary primary team will log NIHSS scores in VistA prior to patient 
enrollment. Specialized, dedicated communication outcome assessors will conduct the 
WAB (Appendix E) and log scores in VistA. SLPs administering MMIT or subsequent 
individualized SLT will log their clinical notes in VistA. An independent research 
assistant who is not involved in other aspects of the study will transfer relevant data from 
VistA into a (CSV format) spreadsheet, and this will be used for statistical analysis.  
3.8 Sample Size Calculation and Site Recruitment 
  Sample size was computed using the statistical software package R (Version 
3.2.0 on Mac OS). Based on prior studies, we expect the between groups mean difference 
from baseline in WAB-AQ to be at least 15.1 at the 3-week assessment, with standard 
deviation of 17.71. Using these values with power of 0.80 and alpha of 0.05, we 
determine a total of N = 46 subjects must complete the primary study endpoint and be 
usable in analysis, in order to detect an effect. (Appendix F). 
Averaging completion rates in the same prior studies, we would expect 61% of 
patients with aphasia on initial NIHSS screening will complete the primary endpoint of 
the study, so we scale recruiting up to a total of N = 76, with 38 patients per arm. 
 Based on historical volumes of stroke patients at each VAMC PSC, we will need 
to run the trial at two VA Stroke Centers, as long as the largest two centers are willing to 
participate (see Appendix G with the details on stroke volume per VAMC). 
The following CONSORT Diagram summarizes the sample size requirements and 
key assessment points.  
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Figure 1: CONSORT Flow diagram of early Modified Melodic Intonation   
                 Therapy trial 
 
3.9 Statistical Analysis 
Baseline patient and stroke characteristics (see Table 2 above) will be compared 
across MMIT and usual care groups using  𝜒2 tests for proportions computed from 
categorical variables and 2-sample t-tests for means of continuous variables. 
Statistical significance of our primary outcome, the between group difference in 
pre- to post-test aphasia severity after 3 weeks as measured by the WAB-AQ, will be 
evaluated with a 2-sample t-test. Although successful randomization should render it 
unnecessary, the pre- to post-test WAB-AQ score difference will also serve as the 
dependent variable in multivariate regression that includes a dummy variable for group 
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(MMIT or usual care) assignment, baseline aphasia severity, center fixed effects, and 
other baseline characteristics that may confound results. The coefficient on the group 
assignment dummy variable is the estimated adjusted score difference, and its 
significance will be evaluated with a t-statistic. 
We will also perform secondary analysis of additional outcomes. Within group 
pre- to post-test scores at 3 weeks (with matched pair t-test to evaluate significance) will 
reveal the order of magnitude of communication improvement over this period. Between 
group difference in pre- to post-test scores at 6 months will be used to evaluate 
persistence of treatment benefit with 2-sample t-test to evaluate significance. We will 
also compare mortality rates at hospital discharge and 6 months between groups and 
between group drop-out rates at 6 months using a 𝜒2 test for difference in proportions, 
and between group differences in treatment volume at 6 months using a 2-sample t-test. 
The level of statistical significance for all tests will be set to p<.05. Analysis will 
be performed on intention-to-treat basis.  
3.10 Timeline, Location, and Resources 
Timeline: Pending IRB approval, study enrollment will commence on January 1, 
2019, and continue on a rolling basis until June 27, 2020, the last date at which new 
patients may be enrolled. Data collection will be completed on December 31, 2010, and 
data analysis will commence on January 1, 2021. 
Personnel: Study-specific research personnel include 2 central research assistants, 
1 statistician, and 1 research assistant per site. Study-specific clinicians include 3 
outcome assessors and at least 2 SLPs trained in MMIT per site. 
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Location: The study coordination center will have headquarters at the Neurology 
Department of the West Haven, CT VAMC at 950 Campbell Avenue, where principle 





CHAPTER 4: CONCLUSION 
4.1 Strengths and Advantages 
 The primary strength of our study is our choice of intervention: MMIT is 
pathophysiologically motivated and supported by abundant case studies and a few 
underpowered RCTs, and its early initiation not only coincides with a period of maximal 
neuroplasticity, but it allows for a test of efficacy since formal therapy is not a part of 
usual care in that period. 
 Our use of VAMCs for study setting also confers many advantages. The VAMC 
provides a homogenous institutional setting with consistency across centers, clinicians, 
and reimbursement in a country where healthcare delivery, settings, and insurance 
coverage vary tremendously and may confound estimates of treatment effects. 
Additionally, using VAMCs we can ensure continuity of care across inpatient and clinic 
settings, so that patients receiving MMIT can be treated by the same SLP over the course 
of their 3-week intervention. Finally, patient data has been meticulously recorded in the 
VA’s VistA EHR software, facilitating collection of patient baseline characteristics, 
whereas in other hospital settings, such data may be missing if a patient is unable to 
communicate and has never presented prior to acute stroke.  
 Finally, we use sound methodology. Using a prospective RCT, we minimize risk 
of selection bias. Our use of multiple centers allows recruitment of a larger sample, 
increasing precision, and greater geographic diversity, increasing generalizability. Our 
use of reliable, validated standard assessment instruments and blinded assessors prevents 
detection bias, enhances reproducibility, and facilitates comparison with other studies. 
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4.2 Limitations and Disadvantages 
The source of many advantages also confers one of our primary limitations: our 
use of the VAMC setting constrains the external validity of our study as the veteran 
population is not representative of the non-veteran U.S. population,1 and is only 9.4% 
female.2 While our sample will underrepresent women, gender has undergone 
considerable scrutiny as a potential confounder, and it has no evidence of an independent 
association with aphasia recovery.3-8 We therefore feel that the many advantages to using 
the VAMC setting are worth this compromise of generalizability. 
Our other limitations are shared with the SLT literature more generality. Like our 
predecessors, we are likely to lose substantial numbers of patients to withdrawal, death, 
and failure to adhere to protocol. Because recruitment of eligible PWA after stroke is 
challenging, while driven by ex-ante power calculation, our sample size is small. While 
randomization should yield comparable groups that allow identification of treatment 
effects, in small samples, randomization is more likely to result in baseline differences 
across study groups. Additionally, we must exert caution in interpreting performance on 
language assessments; even in healthy persons without aphasia, individual heterogeneity 
in hearing ability, literacy, premorbid intelligence, and medical risks may influence 
performance, so all errors on language assessments are not due to aphasia.9 However, our 
use of randomization should eliminate any systematic variation in these factors. Finally, 
as is true of all SLT studies, our results do not generalize to other types, timing, or 
intensity of therapy, so our contribution to the deficient SLT evidence base will still be 
incremental. 
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4.3 Clinical Significance 
 An estimated 180,000 individuals in the U.S. are newly diagnosed with aphasia 
each year.10 Aphasia is associated with high morbidity and mortality that can persist into 
the long term.3,11-13 Many patients recover at least incompletely,3 and clinical guidelines 
recommend SLT,14 but they provide no insight into its optimal parameters. Our study is a 
response to numerous calls for an adequately powered RCT to shed light on the ideal type 
and timing of SLT. With individual hetereogeneity across patients, SLT can never be 
“one size fits all.” However, if our results support the efficacy of MMIT compared to the 
common practice of deferring therapy in patients within the first days after stroke, they 
may motivate providers to start MMIT therapy before patients are discharged from their 
acute hospital stays, either as a precursor or adjunt to longer term aphasia therapies, and 
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APPENDIX A: ABBREVIATIONS 
 
VAMC  Veterans Administration Medical Center 
VA/DoD Veterans Administration/ Department of Defense 
AHA/ASA American Heart Association/ American Stroke Association 
PWA   persons with aphasia 
RCT  randomized controlled trial 
SLP  speech language pathologist 
MIT  Melodic Intonation Therapy 
SLT  speech language therapy (broadly speaking, includes all  
   therapeutic approaches) 
MMIT  Modified Melodic Intonation Therapy 
WAB-AQ Western Aphasia Battery-Aphasia Quotient 
PICA  Porch Index of Communicative Ability 
fMRI  functional magnetic resonance imaging 
DTI  Diffusor Tensor Imaging 
PET  positive emission topography 
AAT  Aaschen Aphasia Test 
ANELT Amsterdam-Nijmegen Everyday Language Test 
PSC  Primary Stroke Center 
UC  usual Care 
ITT  intention to treat 
NIHSS  National Institutes of Health Stroke Scale 
VistA  Veterans Health Information System and Technology Architecture 
AHCPR Agency for Health Care Policy and Research 
REDCap  Research Electronic Data Capture  
OR  odds ratio 
CI  confidence interval 










This letter is to inform you of an upcoming single-blinded, randomized, controlled trial to 
assess the impact of Melodic Intonation Therapy (MIT), a structured therapy that makes 
use of melody, rhythm, and emphasis, on patients with aphasia following an acute stroke. 
 
While the American Heart Association/American Stroke Association (AHA/ASA) 
recommends speech and language therapy for individuals with stroke-induced aphasia, 
there are no guidelines for timing, format, intensity, frequency, or duration of treatment. 
Patients typically do not start receiving speech and language therapy until several weeks 
after stroke. Case studies and observational studies and a small scale RCT suggest that 
patients who receive MIT showed language improvement, and MIT is a therapy that 
seems especially well suited to the critical period of neuroplasticity in the first few weeks 
after stroke. We are proposing a randomized control trial to compare MIT to usual care in 
patients with aphasia due to a stroke during the first three weeks following a stroke. We 





1. Age >= 18 
2. First ever acute stroke, radiologically confirmed (CT or MRI) 
3. Left sided lesion 
4. NIHSS language score of 1 or 2 within 24 hours of admission 
5. Able to react to verbal commands (need not be fully alert) 
6. Native/ primary English speaker 
7. Able to consent/ undergo treatment 
Exclusion  
1. Age >= 18 
2. Requiring ICU transfer or hospice care  
3. Concurrent ACS or decompensated heart failure 
4. Right sided or bi-hemispheric lesion 
5. Prior stroke, lesions, neurological or communication disorders, severe dementia, 
severe depression 
6. Uncorrectable hearing deficit 
7. Prior exposure to MIT 
8. Unable to consent/ undergo treatment 
 
Patients who meet the entry criteria will then be randomized to one of two arms in the 
study. Patients randomized to the MIT arm will receive a modified form of MIT. The 
 64 
dose of our intervention will be a total of 45 minutes per day, 5 days per week, over the 
3-week experimental period, and the 45 minutes per day may be accomplished through 
three time-spaced sessions that takes 10-15 minutes to complete. During the first three 
weeks of the study, patients in the control arm will receive usual care, which consists of a 
swallow study and a speech assessment per the usual protocol at the VAMC. After the 
initial three week period, patients in both arms will be scheduled for outpatient therapy 
PRN as usual. The main outcome of this study is the difference between groups of the 
mean difference from baseline in aphasia severity as measured by the Western Aphasia 
Battery, at 3 weeks and at 6 months after enrollment.  
 
The participation of your institution in this study would help with recruitment and would 
be greatly beneficial in determining the impact of early MIT therapy on aphasia recovery. 
You will be receiving a follow-up phone call in the next two weeks to answer any 
specific questions or concerns your facility may have regarding the involvement in this 
study. Please do not hesitate to contact us (information below) prior to speaking on the 
phone. 
 
Thank you for your time and we look forward to working with you. 





























Form downloaded from http://www.acutestroke.org/  
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APPENDIX G: ESTIMATED PATIENTS BY CENTER 
 
 
(a) Stroke volume data from Bravata D, Myers L, Sico J, Graham G, Arling G, 
Williams L. Examination of Healthcare Utilization Patterns of Post-Stroke Veterans. 
AHA/ASA International Stroke Conference; 2018; Los Angeles. 
(b) Assumes 31% (midpoint of 24-38 from epidemiological studies) of acute stroke 
patients will present with aphasia based on the National Institute of Health Stroke 
Scale (NIHSS) 
(c) Assumes 61% (midpoint of 45-77 from RCTs with CONSORT diagrams) of 
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